Targeting adenoviruses with small molecule inhibitors
Small Molecule Inhibitors Targeting Adenovirus
This study is working on creating new medications that can help fight adenovirus infections, especially for people with weakened immune systems, by finding easier-to-take pills that work better than current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project ID | NIH-10540736 on NIH RePORTER |
What this research studies
This research focuses on developing small molecule inhibitors to combat adenovirus infections, which pose significant health risks, especially to immune-compromised individuals. The approach involves synthesizing and testing new prodrugs that are more effective and have better bioavailability than existing treatments. By utilizing advanced cell culture techniques, the research aims to identify compounds that can be administered orally, reducing the need for intravenous treatment. The ultimate goal is to provide a safer and more effective antiviral option for patients affected by adenovirus infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who are at risk of adenovirus infections, particularly those who are immunocompromised.
Not a fit: Patients who are not immunocompromised or those who do not have a history of adenovirus infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer antiviral treatments for adenovirus infections.
How similar studies have performed: Other research has shown promise in developing antiviral agents for adenoviruses, but this approach is innovative and aims to improve upon existing treatments.
Where this research is happening
Los Angeles, UNITED STATES
- University of Southern California — Los Angeles, United States (Active)
Researchers
- Principal investigator: Mckenna, Charles E — University of Southern California
- Study coordinator: Mckenna, Charles E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.